Skip to main content
Third Circuit· 8/21/2017

In Re Lipitor Antitrust Litigation

Citations

  • 868 F.3d 231

How courts have described this case

Verbatim parenthetical descriptions written by other courts when citing this decision. Ranked by citation-network relevance.

  • “A patent’s reissuance by the PTO does not bar a later finding that the patent was originally procured by fraud.”
  • improper to “[t]ak[e] judicial notice of the truth of the contents of a filing from a related action” (citation omitted)
  • “[A] reverse payment underlying an Actavis antitrust claim need not be in cash form.” (citing King Drug Co. of Florence, Inc. v. SmithKline Beecham Corp., 791 F.3d 388, 403–09 (3d Cir. 2015)); In re EpiPen (Epinephrine, USP
  • “Petitions to administrative agencies are consequently also immune from antitrust liability.”
  • \to conclude [that 10x and Harvard] did not submit[] a sham petition not supported by science requires an evaluation of the scientific merit of [10x and Harvard's] petition. Such an inquiry is unsuitable for resolution on a motion to dismiss.\
  • private settlement agreement submitted to government

Source: CourtListener parenthetical corpus (CC0).

Judges: Smith, Ambro, Fisher

Read full opinion on CourtListener

Cited by

17 cases in this archive cite this case.

Cites

59 cases in this archive are cited by this case; the 20 most cited are listed.

Other cases named In Re Lipitor Antitrust Litigation

3 other CourtListener records share this case name.

Sourced from CourtListener / Free Law Project (CC0).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.